

# A Oliver Sartor

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6595914/a-oliver-sartor-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

445 papers	16,599 citations	61 h-index	121 g-index
508 ext. papers	20,687 ext. citations	6.1 avg, IF	6.59 L-index

#	Paper	IF	Citations
445	Reply: A VISION of ALSYMPCA.. <i>Journal of Nuclear Medicine</i> , <b>2022</b> , 63, 324-325	8.9	
444	Molecularly targeted radiation in combination with additional agents in advanced prostate cancer <b>2022</b> ,		
443	Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.. <i>Oncologist</i> , <b>2022</b> , 27, 220-227	5.7	0
442	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , <b>2022</b> , 18, 35-45	3.6	0
441	Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer.. <i>Cancer Informatics</i> , <b>2022</b> , 21, 11769351221087046	2.4	0
440	Liquid biopsy AR/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 171-171	2.2	
439	Comparative ctDNA analyses of African-American and Caucasian patients with CRPC.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 24-24	2.2	
438	PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS211-TPS211	2.2	1
437	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 77-77	2.2	1
436	Circulating tumor DNA responses to high-dose testosterone injections in CRPC patients.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 173-173	2.2	
435	68ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS189-TPS189	2.2	
434	Longitudinal ctDNA alterations in germline positive CRPC patients.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 275-275	2.2	
433	PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS210-TPS210	2.2	1
432	Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS206-TPS206	2.2	
431	Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 37-37	2.2	
430	Evaluation of ctDNA alterations in mCRPC patients with germline pathogenic mutations.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 177-177	2.2	
429	DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men.. <i>JNCI Cancer Spectrum</i> , <b>2022</b> , 6, pkab097	4.6	1

428	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200208	2.2	1
427	The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.. <i>Lancet, The</i> , <b>2022</b> , 399, 1886-1901	4.0	4
426	Neutropenia, neutrophilia, and neutrophil/lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 175883592211000	5.4	0
425	Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations. <i>Journal of Nuclear Medicine</i> , <b>2022</b> , 63, 823-829	8.9	0
424	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , <b>2021</b> ,	10.2	4
423	Nuclear medicine theranostics comes of age. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1497-1498	21.7	3
422	Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. <i>Prostate</i> , <b>2021</b> , 81, 427-432	4.2	2
421	Increasing Readiness for Early Integrated Palliative Oncology Care: Development and Initial Evaluation of the EMPOWER 2 Intervention. <i>Journal of Pain and Symptom Management</i> , <b>2021</b> , 62, 987-996	4.8	2
420	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1371-1382	2.2	22
419	Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis. <i>Cancer Prevention Research</i> , <b>2021</b> , 14, 741-752	3.2	0
418	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 433-439	4.2	8
417	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. <i>Oncologist</i> , <b>2021</b> , 26, e1179-e1188	5.7	1
416	Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings. <i>Prostate</i> , <b>2021</b> , 81, 657-666	4.2	1
415	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , <b>2021</b> , 127, 2954-2965	6.4	7
414	A Novel Controlled PTEN-Knockout Mouse Model for Prostate Cancer Study. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 696537	5.6	1
413	Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	3
412	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4746-4756	12.9	4
411	Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. <i>Oncologist</i> , <b>2021</b> , 26, 751-760	5.7	2

410	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	2
409	Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 52-62	2.8	7
408	Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). <i>EClinicalMedicine</i> , <b>2021</b> , 31, 100693	11.3	1
407	PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. <i>Oncologist</i> , <b>2021</b> , 26, e115-e129	5.7	20
406	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1623-1630	12.9	12
405	Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 146-148	8.9	10
404	Changes in taste and smell of food during prostate cancer treatment. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 2807-2809	3.9	1
403	Prospective Observational Study of a Racially Diverse Group of Men on Active Surveillance for Prostate Cancer. <i>Urology</i> , <b>2021</b> , 148, 203-210	1.6	2
402	Treating the patient and not just the cancer: therapeutic burden in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 647-661	6.2	2
401	PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 87-87	2.2	
400	EDITORIAL COMMENT. <i>Urology</i> , <b>2021</b> , 148, 140	1.6	
399	ctDNA pathogenic variants (PVs) in homologous recombination repair (HRR) genes in patients with metastatic CRPC.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 138-138	2.2	
398	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , <b>2021</b> , 80, 243-253	10.2	3
397	Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients". <i>Prostate</i> , <b>2021</b> , 81, 1262-1263	4.2	
396	Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1091-1103	59.2	202
395	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. <i>Prostate</i> , <b>2021</b> , 81, 1382-1389	4.2	1
394	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2021692	10.4	19
393	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 680-688	6.2	9

392	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3032-3041	2.2	13
391	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2798-2811	2.2	80
390	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , <b>2020</b> , 126, 2935-2937	6.4	
389	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , <b>2020</b> , 6, 735-743	13.4	23
388	Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer. <i>Oncologist</i> , <b>2020</b> , 25, e1421-e1422	5.7	2
387	End of an era for erythropoiesis-stimulating agents in oncology. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2829-2835	7.5	3
386	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2020</b> , 23, 517-526	6.2	48
385	Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2020</b> , 26, 21-28	2.2	1
384	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2546-2555	12.9	18
383	Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 327-333	5.7	11
382	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , <b>2020</b> , 77, 508-547	10.2	155
381	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2091-2102	59.2	550
380	CD4 T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion. <i>Prostate</i> , <b>2020</b> , 80, 764-776	4.2	3
379	SEER and Gene Expression Data Analysis Deciphers Racial Disparity Patterns in Prostate Cancer Mortality and the Public Health Implication. <i>Scientific Reports</i> , <b>2020</b> , 10, 6820	4.9	6
378	Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5542-5542	2.2	1
377	Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e17592-e17592	2.2	1
376	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 32-32	2.2	1
375	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. <i>Oncotarget</i> , <b>2020</b> , 11, 15-21	3.3	4

374	Inherited DNA-repair gene mutations in African American men with prostate cancer. <i>Oncotarget</i> , <b>2020</b> , 11, 440-442	3.3	9
373	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 284-294	3.3	37
372	Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e312-e314	3.3	1
371	PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. <i>Prostate</i> , <b>2020</b> , 80, 99-108	4.2	21
370	TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 148-154	3.3	4
369	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. <i>JAMA Oncology</i> , <b>2020</b> , 6, 206-216	13.4	10
368	Germline BLM mutations and metastatic prostate cancer. <i>Prostate</i> , <b>2020</b> , 80, 235-237	4.2	8
367	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , <b>2020</b> , 24, 100193	2	1
366	End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. <i>PLoS ONE</i> , <b>2020</b> , 15, e0234541	3.7	2
365	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 581189	5.3	5
364	Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
363	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA <b>2020</b> , 8,		25
362	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2345-2357	59.2	143
361	Distress among African American and White adults with cancer in Louisiana. <i>Journal of Psychosocial Oncology</i> , <b>2020</b> , 38, 63-72	2.8	2
360	-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 370-381	3.6	66
359	Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. <i>Prostate</i> , <b>2019</b> , 79, 1683-1694	4.2	10
358	High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 476-479	3.3	1
357	Germline Variants in Highly Selected Patients With Prostate Cancer-In Reply. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1369	13.4	1



356	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	13
355	Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 524	4.8	8
354	Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , <b>2019</b> , 20, 100151	2	3
353	The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, 321-330	7.1	22
352	Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or $\alpha$ -	8.4	28
351	Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1159-1168	2.2	62
350	Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. <i>JAMA Oncology</i> , <b>2019</b> , 5, 523-528	13.4	111
349	Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. <i>Oncogene</i> , <b>2019</b> , 38, 7060-7072	9.2	18
348	Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219521	3.7	4
347	Reply to J.B. Aragon-Ching. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2297-2298	2.2	
346	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , <b>2019</b> , 125, 4172-4180	6.4	34
345	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 621-627	4	4
344	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5035-5035	2.2	4
343	VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of $^{177}\text{Lu}$ -PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS5099-TPS5099	2.2	18
342	A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 180-180	2.2	1
341	Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 253-253	2.2	3
340	Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 255-255	2.2	1
339	Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 256-256	2.2	8

338	Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 319-319	2.2	4
337	Germline heterozygous BLM mutations and prostate cancer risk.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 321-321	2.2	1
336	Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2019</b> , 71, 445-456	4.4	4
335	Germline DNA repair mutations in men with prostate cancer are less frequent in African Americans as compared with Caucasians.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 258-258	2.2	0
334	Low incidence of microsurgies with biodegradable polymer-delivered, subcutaneously-administered leuprolide acetate in prostate cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 158-158	2.2	
333	Evaluation of circulating tumor DNA (ctDNA) with respect to germline alterations in metastatic castrate resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 254-254	2.2	
332	Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 320-320	2.2	
331	Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 222-222	2.2	
330	DNA repair germline pathogenic mutation associations with treatment duration and family history in prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 245-245	2.2	
329	Aberrations in androgen receptor ctDNA varies by race in metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 247-247	2.2	
328	Late administration of luteinizing hormone-releasing hormone (LHRH) agonists and the impact on testosterone suppression in the real-world management of prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 149-149	2.2	
327	Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 226-226	2.2	
326	TP53 mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 249-249	2.2	
325	ctDNA and copy-number variant quantification in mCRPC at the time of progression.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 265-265	2.2	
324	Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5032-5032	2.2	
323	Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5058-5058	2.2	
322	AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5058-5058	2.2	
321	AGE-RELATED ELEVATED CD4+ T HELPER 17 CELL RESPONSE PROMOTES PROSTATE CANCER CELL GROWTH, MIGRATION, AND INVASION. <i>Innovation in Aging</i> , <b>2019</b> , 3, S879-S879	0.1	78



320	Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. <i>Oncologist</i> , <b>2019</b> , 24, 537-548	5.7	9
319	Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs. <i>Oncologist</i> , <b>2019</b> , 24, 291-292	5.7	2
318	Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 444-448	5.7	13
317	Androgen deprivation therapy in prostate cancer: new findings and questions for the future. <i>Lancet Oncology</i> , <b>2019</b> , 20, 176-177	21.7	4
316	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , <b>2019</b> , 125, 1459-1469	6.4	25
315	Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>European Urology</i> , <b>2018</b> , 74, 283-291	10.2	54
314	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 645-657	59.2	224
313	Extreme Prostate-Specific Antigen Response to Infusional 5-Fluorouracil in Castrate-Resistant Prostate Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 383-385	5.7	0
312	First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 695-701	4	5
311	Editorial Comment. <i>Urology</i> , <b>2018</b> , 113, 144-145	1.6	
310	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , <b>2018</b> , 78, 775-789	4.2	25
309	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1653-1654	59.2	37
308	Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 791-797	5.7	9
307	Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 301-304	4.5	10
306	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , <b>2018</b> , 73, 178-211	10.2	313
305	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. <i>European Urology</i> , <b>2018</b> , 73, 427-435	10.2	57
304	Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. <i>Future Oncology</i> , <b>2018</b> , 14, 2543-2556	3.6	30
303	Editorial Comment. <i>Urology</i> , <b>2018</b> , 118, 125-126	1.6	

302	Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 313-317	3.3	14
301	Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12097-12097	2.2	1
300	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e17018-e17018	2.2	1
299	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, LBA5009-LBA5009	2.2	13
298	First interim results of the Radium-223 (Ra-223) reassure observational study in metastatic castration-resistant prostate cancer (mCRPC): Safety and baseline (BL) characteristics of U.S. patients (Pts) by prior/concomitant treatment (Tx).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 233-233	2.2	1
297	PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 272-272	2.2	2
296	Detection of actionable BRAF missense mutations by ctDNA-based genomic analysis in prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 306-306	2.2	2
295	Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS399-TPS399	2.2	14
294	Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 224-224	2.2	1
293	cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 256-256	2.2	
292	cfDNA TP53 mutations with treatment history and disease progression in metastatic CRPC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 263-263	2.2	
291	c15-162: Phase IB trial of radium 223 and niraparib in patients with castrate resistant prostate cancer (NiraRad).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS385-TPS385	2.2	
290	A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 352-352	2.2	
289	Initial whole blood-based gene expression profile assays in mCRPC pts.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 370-370	2.2	
288	Testosterone (T) suppression by weight and age groups in four pivotal trials of in-situ forming polymer-delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 172-172	2.2	
287	Serum-based biomarkers and liver metastases in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 372-372	2.2	
286	Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 261-261	2.2	
285	Germline pathologic mutations and cancer family history in prostate cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 378-378	2.2	

284	Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 314-314	2.2	
283	Cell-free DNA (cfDNA) analysis and evaluation of BRAF amplifications and mutations in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 255-255	2.2	
282	Continuous infusion fluorouracil (5FU) in heavily pre-treated mCRPC patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 257-257	2.2	
281	Onset and maintenance of testosterone suppression in four pivotal trials of subcutaneously administered leuprolide acetate formulated with in-situ forming polymeric delivery technology.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 205-205	2.2	
280	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5041-5041	2.2	
279	Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5048-5048	2.2	
278	A novel, open-access data commons for improved disease management in patients (pts) with Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21544-e21544	2.2	
277	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , <b>2018</b> , 23, 193-202	5.7	51
276	Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 372-381	7.1	15
275	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 414-424	2.2	107
274	Radium and other alpha emitters in prostate cancer. <i>Translational Andrology and Urology</i> , <b>2018</b> , 7, 436-444	4.4	14
273	Radiotherapy of Skeletal Metastases <b>2018</b> , 809-815		
272	Conflicts of Interest, Baselga, and Clinical Trialists. <i>Oncologist</i> , <b>2018</b> , 23, 1394	5.7	1
271	Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e501-e502	3.3	9
270	Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 417-428	59.2	363
269	Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2017</b> , 67, 245-253	220.7	161
268	Navigating the evolving therapeutic landscape in advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35S, S1-S13	2.8	46
267	Generic drugs in oncology - Authors' reply. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e64	21.7	

266	Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1995-2008	2.5	16
265	The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. <i>Cancer</i> , <b>2017</b> , 123, 3532-3539	6.4	147
264	Editorial Comment. <i>Urology</i> , <b>2017</b> , 102, 171-172	1.6	
263	Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. <i>Cancer</i> , <b>2017</b> , 123, 2489-2496	6.4	14
262	Advantages of a Truly Open-Access Data-Sharing Model. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1178-1181	59.2	54
261	Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 997-998	10.2	2
260	Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 1-6	7.5	37
259	Editorial Comment. <i>Urology</i> , <b>2017</b> , 109, 16-17	1.6	
258	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3189-3197	2.2	168
257	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3097-3104	2.2	215
256	Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). <i>Cancer Medicine</i> , <b>2017</b> , 6, 1541-1551	4.8	15
255	Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e289-e298	3.3	30
254	Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 726-734	12.9	77
253	Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 42-52.e8	3.3	65
252	Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e69-e71	3.3	21
251	Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 59-68	6.6	41
250	Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation. <i>Seminars in Radiation Oncology</i> , <b>2017</b> , 27, 87-93	5.5	1
249	Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e111-e113	3.3	1

248	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 132-142	21.7	90
247	An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes. <i>Biomarker Insights</i> , <b>2017</b> , 12, 1177271917693510	3.5	2
246	Need for re-evaluation of current guidelines based on results from germline genetic testing in prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5009-5009	2.2	4
245	Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5038-5038	3.2	5
244	Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5042-5042	2.2	1
243	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5091-TPS5091	2.2	8
242	Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 192-192	2.2	1
241	Utility of PCA3 and TMPRSS2: ERG urinary biomarkers to predict pathologic outcomes in African American men undergoing radical prostatectomy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e547-e547	2.2	
240	Evidence of linkage in MSH6-associated region exclusive to high-risk African-American families with prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 180-180	2.2	
239	Taste and prostate cancer: Preliminary data on a novel patient-reported outcomes.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 201-201	2.2	
238	Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 216-216	2.2	
237	Outcomes of men who underwent treatment for prostate cancer from a prospective follow up of a racially diverse, multi-institutional active surveillance cohort.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e536-e536	2.2	
236	Treatment sequencing of abiraterone and enzalutamide in patients with mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 233-233	2.2	
235	Liver metastases in mCRPC patients post-therapy with abiraterone (Abi) and/or abiraterone/enzalutamide (Enza).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 250-250	2.2	
234	Family history, race, and prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 225-225	2.2	
233	Characterization of cancer family history among patients with PCa cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 272-272	2.2	
232	Baseline differences in characteristics of a racially diverse group of men electing active surveillance.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 103-103	2.2	
231	Association of cfDNA androgen receptor amplifications with BRAF alterations in mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 234-234	2.2	

230	Inherited pathologic mutations and family history in patients with prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 185-185	2.2	
229	AR amplification eradication with high-dose testosterone (T) in patients with heavily pretreated mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 251-251	2.2	
228	Germline variants and family history in caucasian and African-American prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16548-e16548	2.2	1
227	Generic oncology drugs: are they all safe?. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e493-e501	21.7	27
226	Prostate cancer: What is the optimal treatment sequence for mCRPC?. <i>Nature Reviews Urology</i> , <b>2016</b> , 13, 639-640	5.5	
225	Isotope Therapy for Castrate-Resistant Prostate Cancer: Unique Sequencing and Combinations. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 342-346	2.2	2
224	Racial variation in prostate needle biopsy templates directed anterior to the peripheral zone. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 336.e1-6	2.8	2
223	Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. <i>European Journal of Cancer</i> , <b>2016</b> , 56, 93-100	7.5	50
222	Alternative Digit Ratios and Their Relationship to Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 149-52	3.3	6
221	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1402-18	2.2	666
220	Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. <i>JAMA Oncology</i> , <b>2016</b> , 2, 134-6	13.4	13
219	Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5014-5014	2.2	3
218	Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5023-5023	2.2	4
217	Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5064-5064	2.2	1
216	Docetaxel in the treatment of metastatic hormone-sensitive and castration-resistant prostate cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16505-e16505	2.2	1
215	Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 193-193	2.2	1
214	Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 194-194	2.2	1
213	NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3-3	2.2	6



212	Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. <i>Journal of Community and Supportive Oncology</i> , <b>2016</b> , 14, 54-65		23
211	Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor. <i>Oncotarget</i> , <b>2016</b> , 7, 13651-66	3.3	23
210	Race, inflammation, and prostate cancer: A comparison of African Americans and Caucasians.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 246-246	2.2	
209	Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 320-320	2.2	
208	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16503-e16503	2.2	
207	Characteristics and anticancer interventions (ACIs) in African American (AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T (sip-T): Real-world experience from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5025-5025	2.2	1
206	Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , <b>2016</b> , 88, 72-3	1.6	
205	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. <i>European Urology</i> , <b>2016</b> , 70, 875-883	10.2	53
204	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma <b>2016</b> , 4, 92		25
203	Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 139-48	3.3	1
202	African American Participation in Oncology Clinical Trials--Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 105-16	3.3	20
201	Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. <i>Journal of Urology</i> , <b>2016</b> , 196, 1053-60	2.5	16
200	A Whole Blood Assay for AR-V7 and AR in Patients with Prostate Cancer. <i>Journal of Urology</i> , <b>2016</b> , 196, 1758-1763	2.5	38
199	Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. <i>Prostate</i> , <b>2016</b> , 76, 905-16	4.2	49
198	Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e205-e208	3.3	23
197	Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. <i>Cancer Research</i> , <b>2015</b> , 75, 3663-71	10.1	122
196	Population-Based Assessment of Determining Treatments for Prostate Cancer. <i>JAMA Oncology</i> , <b>2015</b> , 1, 67-8	13.4	
195	A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1555-69	7.5	12

194	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. <i>European Urology</i> , <b>2015</b> , 68, 850-8	10.2	58
193	Independent data monitoring committees: an update and overview. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 143-8	2.8	10
192	Treatment of skeletal metastases with 223Ra-chloride. <i>Clinical and Translational Imaging</i> , <b>2015</b> , 3, 159-165		1
191	Radium-223 in the treatment of osteoblastic metastases: a critical clinical review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 91, 898-906	4	37
190	Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 101-12	3.3	22
189	Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1465-74	5.5	15
188	Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. <i>European Urology</i> , <b>2015</b> , 67, 310-8	10.2	32
187	Neoadjuvant Tyrosine Kinase Downstaging of T2 Renal Cell Carcinoma in Solitary Kidney Before Robotic Partial Nephrectomy. <i>Journal of Endourology Case Reports</i> , <b>2015</b> , 1, 47-9	0.3	2
186	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, djv261	9.7	35
185	Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16027-e16027	2.2	1
184	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA5002-LBA5002	2.2	10
183	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA5002-LBA5002	2.2	45
182	Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 272-272	2.2	2
181	Clinical performance of PCA3 and TMPRSS2:ERG urinary biomarkers for African American men undergoing prostate biopsy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 91-91	2.2	1
180	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. <i>Oncotarget</i> , <b>2015</b> , 6, 23358-71	3.3	67
179	Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2015</b> , 17, 439-40	2.8	6
178	Racial variation in positive prostate needle biopsy templates, which include the transition zone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 125-125	2.2	
177	Clinical practice patterns of Radium-223 (R223) utilization and variables associated with completion of therapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16076-e16076	2.2	

176	Unexpected pegensatide failure: Plea for an extension of an effective FDA early warning system.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17625-e17625	2.2	
175	The Melbourne Consensus Statement on the early detection of prostate cancer. <i>BJU International</i> , <b>2014</b> , 113, 186-8	5.6	50
174	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1397-406	21.7	263
173	Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. <i>Oncologist</i> , <b>2014</b> , 19, 1012-8	5.7	11
172	Editorial comment. <i>Urology</i> , <b>2014</b> , 84, 1072	1.6	
171	Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 504-6	19.4	2
170	Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 91, 248-56	7	21
169	Castration-resistant prostate cancer: adaptive responses in the androgen axis. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 426-33	14.4	97
168	Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. <i>Stem Cells</i> , <b>2014</b> , 32, 983-97	5.8	187
167	Metastatic Cancer of Cowper's Gland: A Rare Cancer Managed Successfully by Molecular Profiling. <i>Case Reports in Oncology</i> , <b>2014</b> , 7, 52-7	1	3
166	Radium-223 in metastatic castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 348-53	9	
165	Long-term survival of participants in the prostate cancer prevention trial. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 413-4	2.8	4
164	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3391-9	2.2	101
163	Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. <i>Cancer</i> , <b>2014</b> , 120, 4006-7	6.4	1
162	Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. <i>Cancer</i> , <b>2014</b> , 120, 2464-71	6.4	94
161	Regulatory and clinical considerations for biosimilar oncology drugs. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e594-e605	21.7	86
160	Active surveillance of prostate cancer in African American men. <i>Urology</i> , <b>2014</b> , 84, 1255-61	1.6	16
159	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 738-46	21.7	357

158	Castration-resistant prostate cancer: from new pathophysiology to new treatment. <i>European Urology</i> , <b>2014</b> , 65, 289-99	10.2	94
157	1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5070-5070	2.2	1
156	Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 185-185	2.2	1
155	Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. <i>Oncotarget</i> , <b>2014</b> , 5, 1646-56	3.3	138
154	Treatment sequencing in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 426-31	2.8	36
153	Management of localized prostate cancer: the pendulum swings (back to the middle). <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 570-1	2.8	1
152	Reappraisal of glucocorticoids in castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 666	2.8	5
151	Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 2225-33	7.5	20
150	Abiraterone and its place in the treatment of metastatic CRPC. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 6-8	19.4	10
149	Targeted radio-nuclide therapy of skeletal metastases. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 18-26	14.4	39
148	Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. <i>European Urology</i> , <b>2013</b> , 64, 722-30	10.2	43
147	Clinicians versus nomogram: predicting future technetium-99m bone scan positivity in patients with rising prostate-specific antigen after radical prostatectomy for prostate cancer. <i>Urology</i> , <b>2013</b> , 81, 956-61	1.6	39
146	Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. <i>Urology</i> , <b>2013</b> , 81, 130-4	1.6	19
145	20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 1277-87	7.5	26
144	Radium-223 in prostate cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1659-60	59.2	35
143	Unmet needs in the prediction and detection of metastases in prostate cancer. <i>Oncologist</i> , <b>2013</b> , 18, 549-57	5.7	30
142	Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1729-37	9.7	113
141	Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3944-50	2.2	71

140	Enzalutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 679-85	4.1	15
139	Characterization of germline copy number variation in high-risk African American families with prostate cancer. <i>Prostate</i> , <b>2013</b> , 73, 614-23	4.2	20
138	Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients. <i>OncoTargets and Therapy</i> , <b>2013</b> , 6, 725-32	4.4	8
137	Splicing variants of androgen receptor in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , <b>2013</b> , 1, 18-24	1.6	8
136	Current clinical challenges in prostate cancer. <i>Translational Andrology and Urology</i> , <b>2013</b> , 2, 122-36	2.3	22
135	Fatal and Serious Anaphylaxis Following Peginesatide Administration. <i>Blood</i> , <b>2013</b> , 122, 5612-5612	2.2	
134	Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis. <i>Blood</i> , <b>2013</b> , 122, 2938-2938	2.2	
133	Surveillance for prostate cancer: are the proceduralists running amok?. <i>Oncology</i> , <b>2013</b> , 27, 523, 593	1.8	
132	Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. <i>European Urology</i> , <b>2012</b> , 61, 549-59	10.2	133
131	Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. <i>BJU International</i> , <b>2012</b> , 110, 201-5	5.6	16
130	Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). <i>BJU International</i> , <b>2012</b> , 110, 328-35	5.6	18
129	Underutilization of partial nephrectomy for stage T1 renal cell carcinoma in the United States, trends from 2000 to 2008. A long way to go. <i>Clinical Genitourinary Cancer</i> , <b>2012</b> , 10, 219-24	3.3	19
128	Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. <i>Cancer Research</i> , <b>2012</b> , 72, 2589-99	10.1	73
127	Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5888-901	12.9	92
126	Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). <i>Journal of General Internal Medicine</i> , <b>2012</b> , 27, 1697-703	4	25
125	State-of-the-Art Management for the Patient with Castration-Resistant Prostate Cancer in 2012. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 289-91	7.1	6
124	Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 in African American prostate cancer families from Louisiana. <i>Prostate</i> , <b>2012</b> , 72, 938-47	4.2	13
123	Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. <i>Journal of Oncology Practice</i> , <b>2012</b> , 8, 84-90	3.1	12

122	Radiation-based approaches for therapy and palliation of advanced prostate cancer. <i>Current Opinion in Urology</i> , <b>2012</b> , 22, 183-9	2.8	4
121	A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , <b>2012</b> , 38, 783-96	5.3	30
120	Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 11252-7	11.5	82
119	A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. <i>Journal of Oncology Practice</i> , <b>2012</b> , 8, e158-67	3.1	4
118	Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. <i>CKJ: Clinical Kidney Journal</i> , <b>2012</b> , 5, 82-88	4.5	67
117	First-line use of cabazitaxel in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS4696-TPS4696	2.2	1
116	Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA4512-LBA4512	2.2	28
115	Implications of the prostate intervention versus observation trial (PIVOT). <i>Asian Journal of Andrology</i> , <b>2012</b> , 14, 803-4	2.8	4
114	Experimental therapeutics in prostate cancer: where are we now and where do we need to go. <i>Asian Journal of Andrology</i> , <b>2012</b> , 14, 421-2	2.8	
113	First Estimates of Incidence of Progressive Multifocal Leukoencephalopathy Developing Among 10,459 Non-HIV Lymphoma VA Patients Who Receive Rituximab: Results From the Veterans Administration Database (1999-2012).. <i>Blood</i> , <b>2012</b> , 120, 2752-2752	2.2	
112	Evaluating Conflicts of Interest in Academic Research On Erythropoietin Receptors in the Cancer Setting. <i>Blood</i> , <b>2012</b> , 120, 4695-4695	2.2	
111	Why Is Cancer Care So Expensive: Potential Implications of Fraud and Abuse. <i>Blood</i> , <b>2012</b> , 120, 4275-4275	2.2	
110	Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 783-4	2.8	6
109	Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. <i>Maturitas</i> , <b>2011</b> , 70, 194-6	5	10
108	Cabazitaxel for castration-resistant prostate cancer [Authors' reply. <i>Lancet, The</i> , <b>2011</b> , 377, 122-123	40	10
107	Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. <i>Journal of Hematology and Oncology</i> , <b>2011</b> , 4, 18	22.4	38
106	Berberine suppresses androgen receptor signaling in prostate cancer. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 1346-56	6.1	72
105	Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 515-6	19.4	5



104	Cabazitaxel for the treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2011</b> , 7, 15-24	3.6	12
103	Radiation for bone metastases. <i>Current Opinion in Supportive and Palliative Care</i> , <b>2011</b> , 5, 227-32	2.6	7
102	Overcoming chemotherapy resistance in prostate cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3892-902	12.9	53
101	Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. <i>Oncologist</i> , <b>2011</b> , 16, 1487-97	5.7	21
100	Randomized studies of PSA screening: an opinion. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 364-5	2.8	3
99	Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 366-8	2.8	7
98	Denosumab in bone-metastatic prostate cancer: known effects on skeletal-related events but unknown effects on quality of life. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 612-3	2.8	6
97	Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 683-9	2.8	4
96	Critical appraisal of cabazitaxel in the management of advanced prostate cancer. <i>Clinical Interventions in Aging</i> , <b>2010</b> , 5, 395-402	4	23
95	Androgen receptor sequence and variations in several common prostate cancer cell lines. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 383-8	4.6	3
94	Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2010</b> , 7, 23-29		1
93	The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. <i>Urology</i> , <b>2010</b> , 75, 623-9	1.6	8
92	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1147-54	4 <sup>0</sup>	23 <sup>11</sup>
91	Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2010</b> , 8, 23-8	3.3	10
90	Twists and turns on the way to progress in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2010</b> , 12, 790-2	2.8	0
89	Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4398-405	2.2	63
88	Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7099-105	12.9	59
87	Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3223-30	12.9	44

86	Cytokine genetic polymorphisms and prostate cancer aggressiveness. <i>Carcinogenesis</i> , <b>2009</b> , 30, 1358-62	4.6	48
85	Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2417-8	2.2	7
84	Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3850-5	12.9	22
83	Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5431-8	2.2	268
82	Solitary adrenal metastatic lesion in a patient with a history of prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, 64-6	3.3	1
81	Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, E90-2	3.3	14
80	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. <i>Cancer</i> , <b>2009</b> , 115, 981-7	6.4	87
79	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , <b>2009</b> , 113, 4834-40	2.2	718
78	Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. <i>Canadian Journal of Urology</i> , <b>2009</b> , 16, 4806-12	9.8	10
77	Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. <i>BJU International</i> , <b>2008</b> , 101, 308-12	5.6	37
76	Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naïve prostate cancer metastatic to bone. <i>Clinical Genitourinary Cancer</i> , <b>2008</b> , 6, 40-5	3.3	9
75	Evaluating localized prostate cancer and identifying candidates for focal therapy. <i>Urology</i> , <b>2008</b> , 72, S12-24	2.4	101
74	Prostate cancer: epidemiology and health-related quality of life. <i>Urology</i> , <b>2008</b> , 72, S3-11	1.6	26
73	Counselling the Prostate Cancer Patient. <i>European Urology Supplements</i> , <b>2008</b> , 7, 765-771	0.9	3
72	Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 842-7	2.2	86
71	Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. <i>Prostate</i> , <b>2008</b> , 68, 839-48	4.2	59
70	Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). <i>Cancer</i> , <b>2008</b> , 112, 2393-400	6.4	112
69	Getting to go! for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Blood</i> , <b>2008</b> , 112, 2402-2402	2.2	

68	Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint. <i>Blood</i> , <b>2008</b> , 112, 4681-4681	2.2	
67	Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use. <i>Blood</i> , <b>2008</b> , 112, 4680-4680	2.2	
66	Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines. <i>Blood</i> , <b>2008</b> , 112, 672-672	2.2	2
65	Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. <i>Cancer</i> , <b>2007</b> , 109, 637-43	6.4	102
64	Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.. <i>Blood</i> , <b>2007</b> , 110, 3340-3340	2.2	
63	Eligard <sup>®</sup> 6: A New Form of Treatment for Prostate Cancer. <i>European Urology Supplements</i> , <b>2006</b> , 5, 905-910	2.2	19
62	The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 4, 257-62	3.3	29
61	Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2005</b> , 3, 211-4		4
60	Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2005</b> , 23, 163-7	2.8	2
59	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. <i>BJU International</i> , <b>2005</b> , 96, 783-6	5.6	21
58	Sapoin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. <i>Asian Journal of Andrology</i> , <b>2005</b> , 7, 147-58	2.8	25
57	Amplification and overexpression of prosapoin in prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 44, 351-64	5	42
56	Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 11-21	6.4	24
55	Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8894-905	2.2	7
54	The Research on Adverse Drug Events and Reports (RADAR) project. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 2131-40	27.4	86
53	Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. <i>World Journal of Urology</i> , <b>2004</b> , 22, 425-30	4	11
52	Prosapide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. <i>Prostate</i> , <b>2004</b> , 61, 114-23	4.2	19
51	Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 98-103		27

50	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. <i>Urology</i> , <b>2004</b> , 63, 114-9	1.6	15
49	Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. <i>Urology</i> , <b>2004</b> , 63, 940-5	1.6	273
48	Finasteride, a selective 5-alpha-reductase inhibitor, in the prevention and treatment of human prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 2, 206-8		5
47	Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 2, 209-11		6
46	Improved survival benefit of autologous dendritic cell-based vaccine for hormone refractory prostate cancer: a retrospective subset analysis of the d9901 trial. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 2, 212		2
45	Highlights from the 99th Annual Meeting of the American Urological Association San Francisco, CA May 2004. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 13-17		1
44	Docetaxel improves survival in metastatic androgen-independent prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 18-20		1
43	Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 77-9		3
42	Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 80-2		12
41	Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2004</b> , 3, 141-3		16
40	Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 3859-66	2.2	50
39	Radioisotopic treatment of bone pain from metastatic prostate cancer. <i>Current Oncology Reports</i> , <b>2003</b> , 5, 258-62	6.3	11
38	Prostate-specific antigen doubling time predicts disease progression and survival. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 1, 208-11		1
37	Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 1, 212-4		1
36	High androgen receptor levels are predictive of decreased survival in prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 2, 13-4		11
35	Radical prostatectomy improves cancer-specific survival but not overall survival in early-stage prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 2, 15-7		1
34	Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for patients with hormone-refractory prostate cancer with a Gleason score . <i>Clinical Prostate Cancer</i> , <b>2003</b> , 2, 81-3		4
33	Clinical trials of atrasentan in hormone-refractory prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 2, 84-6		7

32	Eligard: leuprolide acetate in a novel sustained-release delivery system. <i>Urology</i> , <b>2003</b> , 61, 25-31	1.6	122
31	An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. <i>Urology</i> , <b>2003</b> , 62, 319-23	1.6	44
30	Suramin's development: what did we learn?. <i>Investigational New Drugs</i> , <b>2002</b> , 20, 209-19	4.3	57
29	Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3599-604	2.2	86
28	Endpoints in prostate cancer clinical trials. <i>Urology</i> , <b>2002</b> , 60, 101-7; discussion 107-8	1.6	17
27	New treatment modalities for hormone-resistant prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2002</b> , 1, 139-41		
26	Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. <i>International Journal of Cancer</i> , <b>2001</b> , 96, 363-71	7.5	54
25	Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. <i>Urology</i> , <b>2001</b> , 57, 727-32	1.6	104
24	A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2000</b> , 18, 193-7	4.3	17
23	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 3461-7	2.2	839
22	Understanding Barriers to the Early Detection of Prostate Cancer Among Men of Lower Socioeconomic Status. <i>Prostate Journal</i> , <b>1999</b> , 1, 179-184		6
21	Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. <i>Urology</i> , <b>1999</b> , 53, 378-80	1.6	128
20	Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer. <i>Urology</i> , <b>1999</b> , 53, 553-6	1.6	9
19	Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. <i>Urology</i> , <b>1999</b> , 54, 709-13	1.6	91
18	Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. <i>Southern Medical Journal</i> , <b>1999</b> , 92, 415-6	0.6	43
17	Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. <i>Urology</i> , <b>1998</b> , 52, 252-6	1.6	77
16	Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>1997</b> , 89, 134-8	9.7	70
15	Determination of CAG repeat length in the androgen-receptor gene using frozen serum. <i>Urology</i> , <b>1997</b> , 49, 301-4	1.6	7

14	Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. <i>Cancer Investigation</i> , <b>1996</b> , 14, 513-7	2.1	43
13	Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. <i>Cancer Treatment Reviews</i> , <b>1996</b> , 22, 105-18	14.4	9
12	Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. <i>Acta Oncologica</i> , <b>1996</b> , 35, 763-5	3.2	7
11	Mifepristone: antineoplastic studies. <i>Clinical Obstetrics and Gynecology</i> , <b>1996</b> , 39, 498-505	1.7	16
10	Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. <i>American Journal of Medicine</i> , <b>1995</b> , 98, 412-4	2.4	77
9	A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. <i>Cancer</i> , <b>1995</b> , 75, 2159-64	6.4	36
8	Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. <i>Cancer</i> , <b>1995</b> , 76, 453-62	6.4	60
7	Acute renal toxicity associated with suramin in the treatment of prostate cancer. <i>Cancer</i> , <b>1994</b> , 74, 1612-4	6.4	23
6	The detergent Triton X-100 induces a death pattern in human carcinoma cell lines that resembles cytotoxic lymphocyte-induced apoptosis. <i>FEBS Letters</i> , <b>1994</b> , 353, 129-32	3.8	33
5	In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. <i>Anti-Cancer Drugs</i> , <b>1994</b> , 5, 336-42	2.4	7
4	Antigrowth factor strategies. <i>Cancer</i> , <b>1993</b> , 71, 1172-8	6.4	10
3	Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. <i>Biochemical Pharmacology</i> , <b>1993</b> , 46, 1831-40	6.4	127
2	Regulation of the expression of the human preprogastrin-releasing peptide gene and post-translational processing of its gene product. <i>Annals of the New York Academy of Sciences</i> , <b>1988</b> , 547, 30-40	6.5	3
1	The rat prepro gastrin releasing peptide gene is transcribed from two initiation sites in the brain. <i>Molecular Endocrinology</i> , <b>1988</b> , 2, 556-63		46